![]() Under the terms of the agreement, the collaboration between the two companies will extend in 2022 for an additional three years. "Our three clinical initiatives and more than 20 discovery and preclinical programs to date are clear evidence of how productive a partnership we've established." Aarif Khakoo, M.D., head of research and development, Calico, added, "This additional extension validates our original vision and is a testament to the collective efforts of many people from both organizations who are working to deepen our understanding of specific disease pathways and develop novel therapies for patients." "We set out seven years ago to bring forth a unique partnership with AbbVie that we believed could yield both novel insights into the biology of aging and first-in-class targets for age-related diseases," said Arthur D. "The extension of this collaboration enables Calico's world-class scientists and the AbbVie Discovery team to continue to build on the transformative research we've done and advance more preclinical and clinical programs that have first-in-class potential," said Gerry Fox, Ph.D., vice president, Discovery, AbbVie. "Our collaboration has evolved into an innovation engine, particularly for novel targets in the oncology and immuno-oncology space, that could break new ground for challenging, age-related diseases," said Tom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. For instance, the lead immuno-oncology target, currently in Phase I studies, includes two PTPN2 inhibitors, which act at multiple steps in the cancer immunity cycle. Further, AbbVie and Calico have advanced three neurodegeneration and cancer targets into the clinic, with a deep preclinical pipeline behind it. Since 2014, the collaboration has produced more than 20 early-stage programs addressing disease states across immuno-oncology and neurodegeneration and has yielded new insights into the biology of aging. AbbVie provides scientific and clinical development support and will lend its expertise to future commercialization activities. With more than 200 employees, Calico has established a world-class research and development facility in the San Francisco Bay Area.Īs part of the collaboration, working together with AbbVie, Calico pursues discovery-stage research and development utilizing state-of-the-art technology and advanced computing capabilities. Levinson, Ph.D., who previously led Genentech as chairman and CEO. This is the second extension of the collaboration originally established in 2014.Ĭalico is a life sciences company founded by Alphabet together with Calico CEO Arthur D. and SOUTH SAN FRANCISCO, Calif., J/PRNewswire/ - AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. ![]() #Calico company proInternal applications, then our B2B based Bizapedia Pro API™ might be the answer for you.NORTH CHICAGO, Ill. ![]() If you are looking for something more than a web based search utility and need to automate company and officer searches from within your WHAT'S INCLUDED IN THE ADVANCED SEARCH FORM? Utilize our advanced search form to filter the search results by Company Name, City, State, Postal Code, Filing Jurisdiction, Entity Type, Registered Agent,įile Number, Filing Status, and Business Category. While logged in and authenticated, you will not be asked to solve any complicated Recaptcha V2 challenges. In addition, all pages on Bizapedia will be served to you completely ad freeĪnd you will be granted access to view every profile in its entirety, even if the company chooses to hide the private information on their profile from the general public. Your entire office will be able to use your search subscription. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |